Myomo, Inc. Announces Proposed Public Offering of Common Stock
February 07 2019 - 04:05PM
Business Wire
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, today announced that it is proposing to offer
and sell, subject to market conditions, shares of its common stock
in an underwritten public offering. Myomo expects to grant the
underwriter a 45-day option to purchase up to an additional 15% of
the shares of common stock offered in the public offering to cover
over-allotments, if any. All of the shares of common stock are
being offered by the Company. The offering is subject to market and
other conditions and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
National Securities Corporation, a wholly owned subsidiary of
National Holdings Corporation (NASDAQ: NHLD), is acting as sole
book-running manager for the proposed offering.
Myomo intends to use the net proceeds from this offering for
working capital and general corporate purposes.
A shelf registration statement on Form S-3 relating to the
shares of common stock being offered was filed with the Securities
and Exchange Commission (the “SEC”) and is effective. The shares
may be offered only by means of a prospectus. A preliminary
prospectus supplement describing the terms of the offering will be
filed with the SEC and will form a part of the effective
registration statement. Copies of the preliminary prospectus
supplement and the accompanying base prospectus relating to this
offering may be obtained, when available, from: National Securities
Corporation, Attention: Christopher Passarelli, 200 Vesey Street,
25th Floor, New York, New York 10281, telephone: (212) 417-8164 or
by email at prospectusrequest@nationalsecurities.com ; or on the
SEC’s website at http://www.sec.gov.
This announcement shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any offer or sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. For more information, please visit
www.myomo.com.
Safe Harbor
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Registration Statement on Form 10-K, which
can be found on the SEC’s website at www.sec.gov. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190207005797/en/
Investor Relations:Vivian CervantesPCG
Advisory646-863-6274vivian@pcgadvisory.com
Public Relations:Matter CommunicationsSarah
Karr978-518-4817myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2023 to Mar 2024